Science Explorer Back to mapMap
Institution · Amyloidosis Foundation

Most cited papers from Amyloidosis Foundation

What are the most cited papers from Amyloidosis Foundation?

The most cited paper from Amyloidosis Foundation is "Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis" (David H Adams et al., 2018), with 3,046 citations. Next come "Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy" (2,841) and "CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis" (1,751).

Showing 50 of 60 papers. Every paper with more than 169 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis David H Adams et al. · New England Journal of Medicine Open access 4 Jul 2018 3,046
2 Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy Matthew J. Maurer et al. · New England Journal of Medicine Open access 27 Aug 2018 2,841
3 CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis Julian David Gillmore et al. · New England Journal of Medicine Open access 26 Jun 2021 1,751
4 Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia Willemijn J. Jansen et al. · JAMA Open access129 authors 19 May 2015 1,662
5 Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis Merrill Douglas Benson et al. · New England Journal of Medicine Open access 4 Jul 2018 1,454
6 Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis Morie Abraham Gertz, Ray Comenzo, Rodney H. Falk et al. · American Journal of Hematology 2005 1,438
7 Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases Pablo García‐Pavía et al. · European Heart Journal Open access 2 Feb 2021 1,221
8 The Systemic Amyloidoses Rodney H. Falk, Raymond L. Comenzo, Martha Skinner · New England Journal of Medicine 25 Sep 1997 1,194
9 Systemic amyloidosis Ashutosh D. Wechalekar, Julian David Gillmore, Philip Nigel Hawkins · The Lancet 21 Dec 2015 1,006
10 Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis Teresa Coelho et al. · New England Journal of Medicine Open access 28 Aug 2013 981
11 Natural History and Outcome in Systemic AA Amyloidosis Helen J. Lachmann, Hugh J.B. Goodman, Janet A. Gilbertson et al. · New England Journal of Medicine Open access 6 Jun 2007 899
12 Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society Alexander Richard Lyon et al. · European Journal of Heart Failure Open access 28 May 2020 823
13 Natural history and outcome in systemic AA amyloidosis Lachmann, HJ, Goodman, HJB, Gilbertson, JA et al. · UCL Discovery (University College London) 7 Jun 2007 782
14 Repurposing Diflunisal for Familial Amyloid Polyneuropathy John L. Berk et al. · JAMA Open access 25 Dec 2013 711
15 Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis Efstathios Kastritis et al. · New England Journal of Medicine Open access 30 Jun 2021 703
16 Misdiagnosis of Hereditary Amyloidosis as AL (Primary) Amyloidosis Helen Jane Lachmann, David Richmond Booth, Susanne E. Booth et al. · New England Journal of Medicine Open access 6 Jun 2002 689
17 Classification criteria for autoinflammatory recurrent fevers Marco Gattorno et al. · Annals of the Rheumatic Diseases Open access 24 Apr 2019 593
18 Systemic immunoglobulin light chain amyloidosis Giampaolo Merlini, Angela Dispenzieri, Vaishali Sanchorawala et al. · Nature Reviews Disease Primers ReviewOpen access 25 Oct 2018 572
19 Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis Mathew S. Maurer, Sabahat Bokhari, Thibaud Damy et al. · Circulation Heart Failure Open access Sep 2019 563
20 Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy Julian David Gillmore et al. · New England Journal of Medicine Open access 10 Jan 2024 532
21 T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4 + T cells Giuseppina Arbore et al. · Science Open access 16 Jun 2016 524
22 Systemic exosomal siRNA delivery reduced alpha‐synuclein aggregates in brains of transgenic mice Jonathan M. Cooper, Oscar P. B. Wiklander, Joel Z. Nordin et al. · Movement Disorders Open access 11 Aug 2014 515
23 Amyloidosis: Pathogenesis and New Therapeutic Options Giampaolo Merlini, David C. Seldin, Morie Abraham Gertz · Journal of Clinical Oncology Open access 12 Apr 2011 513
24 Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes Fabrizio De Benedetti et al. · New England Journal of Medicine Open access 16 May 2018 489
25 Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis Morie Abraham Gertz, Merrill Douglas Benson, P. James B. Dyck et al. · Journal of the American College of Cardiology Open access 23 Nov 2015 485
26 Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis Scott David Solomon, David H Adams, Arnt V. Kristen et al. · Circulation 17 Jan 2019 465
27 Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy Helen Jane Lachmann, Ruth Gallimore, Julian David Gillmore et al. · British Journal of Haematology Open access 20 Jun 2003 436
28 Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging Adam Castaño, Muhammad Haq, David L. Narotsky et al. · JAMA Cardiology 24 Aug 2016 424
29 Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial David H Adams, Ivailo Tournev, Mark Taylor et al. · Amyloid Open access 23 Jul 2022 401
30 Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component Duncan Richards, Louise M. Cookson, Aliénor Berges et al. · New England Journal of Medicine Open access 15 Jul 2015 382
31 Senile Systemic Amyloidosis Presenting With Heart Failure Belinda Ng, Lawreen Heller Connors, Ravin Davidoff et al. · Archives of Internal Medicine 27 Jun 2005 370
32 Diagnosis and Treatment of Cardiac Amyloidosis. A Position Statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases Pablo García‐Pavía et al. · European Journal of Heart Failure Open access Apr 2021 344
33 The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry Helen Jane Lachmann et al. · Annals of the Rheumatic Diseases Open access 22 Aug 2013 341
34 Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis Mathew S. Maurer et al. · New England Journal of Medicine Open access 25 Oct 2023 335
35 Rapid Proton-Detected NMR Assignment for Proteins with Fast Magic Angle Spinning Emeline Barbet‐Massin et al. · Journal of the American Chemical Society Open access 7 Aug 2014 326
36 Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy David H Adams, Yukio Ando, João Melo Beirão et al. · Journal of Neurology Open access 6 Jan 2020 324
37 Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis Efstathios Kastritis, Ashutosh D. Wechalekar, Meletios Athanasios Dimopoulos et al. · Journal of Clinical Oncology 20 Jan 2010 301
38 Aortic Stenosis and Cardiac Amyloidosis Julien Ternacle, Laura Krapf, Dania Mohty et al. · Journal of the American College of Cardiology Open access Nov 2019 297
39 Systemic Amyloidosis in E ngland: an epidemiological study Jennifer Helen Pinney, Colette J Smith, Jessi B. Taube et al. · British Journal of Haematology Open access 11 Mar 2013 290
40 Intracardiac Thrombosis and Anticoagulation Therapy in Cardiac Amyloidosis DaLi Feng, Imran S. Syed, Matthew W. Martinez et al. · Circulation Open access 4 May 2009 286
41 Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine Giovanni O. Palladini, Paola Rosalba Russo, Tiziana Bosoni et al. · Clinical Chemistry Open access 8 Jan 2009 281
42 Recommendations for the management of autoinflammatory diseases Nienke M. ter Haar et al. · Annals of the Rheumatic Diseases Open access 25 Jun 2015 278
43 Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium Isabelle Lousada, Raymond L. Comenzo, Heather Jolie Landau et al. · Advances in Therapy Open access Oct 2015 277
44 Eprodisate for the Treatment of Renal Disease in AA Amyloidosis Laura M. Dember, Philip Nigel Hawkins, Bouke P. C. Hazenberg et al. · New England Journal of Medicine 6 Jun 2007 274
45 Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis Michele Boldrini et al. · JACC. Cardiovascular imaging Open access 18 Dec 2019 270
46 Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers Silvia Federici et al. · Annals of the Rheumatic Diseases 31 Jan 2015 270
47 Epidemiology of Cardiac Amyloidosis–Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States Lauren Gray Gilstrap, Francesca Dominici, Yun Wang et al. · Circulation Heart Failure Open access Jun 2019 262
48 Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis Mazen A Hanna, Frederick L. Ruberg, Matthew J. Maurer et al. · Journal of the American College of Cardiology Open access Jun 2020 254
49 Evolving landscape in the management of transthyretin amyloidosis Philip Nigel Hawkins, Yukio Ando, Angela Dispenzeri et al. · Annals of Medicine Open access 17 Nov 2015 248
50 Cardiac Amyloidosis Due to Transthyretin Protein Frederick L. Ruberg, Matthew J. Maurer · JAMA Open access 5 Mar 2024 245

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.